Agfa HealthCare is changing the name of Insight Agents to Agfa HealthCare Imaging Agents.

FDG-PET is highly accurate in diagnosing progressive neurodegenerative disease such as Alzheimer’s disease (AD) even if cognitive dysfunction is only mild. Thus, novel brain imaging probes targeting, for instance, beta-amyloid will likely serve a different purpose. They will play an important role if beta-amyloid is confirmed as a molecular target of effective therapy, and drugs that target beta-amyloid are actually developed.